MedEvidence! Truth Behind the Data

Send us Fan Mail
Leslie Byatt joins Dr. Michael Koren to talk about leadership in the clinical research space. The two research professionals discuss the importance of qualified researchers in a research trial and the qualities that make for a good clinical research leader. They also talk about research as a treatment option and the benefits observed in research patients (even those in the placebo arm). They explain that the attention, care, and time with research professionals leads to better understanding and health for those who join, and that's on top of the altruistic benefits to science and health in general.
Be a part of advancing science by participating in clinical research.

Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com

Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube

Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn

Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com

Music: Storyblocks - Corporate Inspired

Thank you for listening!

Send us Fan Mail
A Cardiologist & Nephrologist Go Head-to-Head, er... "Heart-to-Kidney"
Nephrologist Dr. Ali Rawabdeh joins Cardiologist Dr. Michael Koren to debate which is the bigger contributor (and problem) with high blood pressure: the heart or the kidneys. The two doctors discuss this extremely prevalent condition from their competing perspectives and give information on how different body systems can influence blood pressure. they also talk about the importance of understanding that blood pressure varies over time and that individual measurements are not the end-all of determining hypertension. They also dig into lifestyle and medical treatments for high blood pressure and upcoming genetic treatments that are currently being investigated.
Be a part of advancing science by participating in clinical research.

Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com

Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube

Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn

Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com

Music: Storyblocks - Corporate Inspired

Thank you for listening!

Send us Fan Mail
Cardiologists Dr. Seth Baum and Dr. Michael Koren discuss the newly released top-line results from a big Lp(a) study investigating the effects of the drug pelacarsen. They talk about what Lp(a) is, why it matters, happened in the study, and what this means for other pelacarsen and Lp(a) studies worldwide. They take a deep dive into some of the factors that can reduce the effectiveness of clinical trials and explain that this particular failure doesn't undermine the theory behind controlling Lp(a) levels or the potential effectiveness of competing investigational medications. Finally, the companion cardiologists talk about what this means for people who have high Lp(a) and what they can do to help control their risks of associated heart problems.
Be a part of advancing science by participating in clinical research.

Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com

Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube

Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn

Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com

Music: Storyblocks - Corporate Inspired

Thank you for listening!

Send us Fan Mail
Dr. Mitchell Rothstein explains that GLPs have been with us for thousands of years. He gives a brief overview of how these medications work, some of the side effects they can cause, and to mitigate things like muscle loss and GI issues through exercise and dose management.
Be a part of advancing science by participating in clinical research.

Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com

Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube

Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn

Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com

Music: Storyblocks - Corporate Inspired

Thank you for listening!

Send us Fan Mail
Dr. Mitchell Rothstein joins Dr. Michael Koren to discuss a current trend in unapproved medicine: peptides. They investigate what peptides are, why they have become so popular, and the very real problems with getting off-market medicines through the "grey market." They also talk about the history of peptides, including why they were banned from compounding pharmacies and why they are back on the market. Tune in for history, medicine, technical detail, and politics.
Be a part of advancing science by participating in clinical research.

Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.com

Listen on Spotify
Listen on Apple Podcasts
Watch on YouTube

Share with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.

Follow us on Social Media:
Facebook
Instagram
X (Formerly Twitter)
LinkedIn

Want to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.com

Music: Storyblocks - Corporate Inspired

Thank you for listening!